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ABSTRACT
Objectives: Gentamicin and vancomycin are narrow-
therapeutic-index antibiotics with potential for high
toxicity requiring dose individualisation and continuous
monitoring. Clinical decision support (CDS) tools have
been effective in reducing gentamicin and vancomycin
dosing errors. Online dose calculators for these drugs
were implemented in a London National Health Service
hospital. This study aimed to evaluate the impact of
these calculators on the accuracy of gentamicin and
vancomycin initial doses.
Methods: The study used a pre–postintervention
design. Data were collected using electronic patient
records and paper notes. Random samples of
gentamicin and vancomycin initial doses administered
during the 8 months before implementation of the
calculators were assessed retrospectively against
hospital guidelines. Following implementation of the
calculators, doses were assessed prospectively. Any
gentamicin dose not within ±10% and any vancomycin
dose not within ±20% of the guideline-recommended
dose were considered incorrect.
Results: The intranet calculator pages were visited 721
times (gentamicin=333; vancomycin=388) during the 2-
month period following the calculators’ implementation.
Gentamicin dose errors fell from 61.5% (120/195) to
44.2% (95/215), p<0.001. Incorrect vancomycin
loading doses fell from 58.1% (90/155) to 32.4% (46/
142), p<0.001. Incorrect vancomycin first maintenance
doses fell from 55.5% (86/155) to 33.1% (47/142),
p<0.001. Loading and first maintenance vancomycin
doses were both incorrect in 37.4% (58/155) of patients
before and 13.4% (19/142) after calculator
implementation, p<0.001.
Conclusions: This study suggests that gentamicin and
vancomycin dose calculators significantly improved the
prescribing of initial doses of these agents. Therefore,
healthcare organisations should consider using such
CDS tools to support the prescribing of these high-risk
drugs.
BACKGROUND
Gentamicin and vancomycin are narrow-
therapeutic-index antibiotics with potential
for high toxicity and require dose individual-
isation with regular therapeutic drug moni-
toring. The main side effects of gentamicin
are dose-related, and include nephrotoxicity
and irreversible ototoxicity, while the main
side effects of parenteral vancomycin, not
necessarily dose-related, include nephrotox-
icity, normally-reversible ototoxicity and
blood disorders including neutropenia.1
Antibiotics were the most common medica-
tions associated with prescribing errors (39.7%,
276/696) in a US study. Overdosing and under-
dosing accounted for 58.3% of these errors
(406/696).2 Gentamicin and vancomycin are
often poorly prescribed, and dosing errors are
a particular problem. Underdosing may lead to
treatment failure while overdosing can cause
toxicity. An Australian study showed that only
30.3% (40/132) of all gentamicin initial doses
were in accordance with hospital guidelines.3
Strengths and limitations of this study
▪ This study suggests that accuracy of gentamicin
and vancomycin initial doses can be improved
using dose calculators linked to electronic
prescribing.
▪ Dose improvements were demonstrated in mul-
tiple specialities within a large acute teaching
hospital.
▪ Unlike previous studies, this study evaluated the
accuracy of loading and first maintenance doses
of vancomycin.
▪ This study did not assess the clinical and/or
pharmacodynamic outcomes of the calculators.
▪ It was not possible to identify whether individual
doctors who accessed the calculators used the
tool for calculating drug doses prior to prescribing.
▪ The use of different methods to identify patients
precalculators and postcalculators may have led
to differences in patient demographics.
▪ The long-term impact of the calculators (eg,
12 months postimplementation) was not assessed
in this study.
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Another Australian study found that of 60 eligible gentami-
cin initial doses, only 46.7% (n=28) were consistent with
local guidelines.4 A US study conducted in a tertiary-care
hospital identiﬁed that only 50.6% (128/253) of vanco-
mycin initial doses were appropriate according to national
guidelines.5 Fuller et al6 found that only 22.1% (980/4441)
of all vancomycin doses prescribed at a US emergency
department (ED) were correct as per national guidelines.
Narrow-therapeutic-index medications are more likely
to cause adverse drug events (ADEs) and may be more
prone to medication errors. Clinical decision support
(CDS) may therefore be of particular value for these
high-risk medications.7 A number of CDS tools have
been shown to be effective in reducing gentamicin/
vancomycin dosing errors. One of these tools,
‘Pharmacist-to-Dose’, a computerised request sent by the
prescriber to the pharmacist for dosing guidance on
vancomycin and aminoglycosides, was evaluated by
Vincent et al. This tool signiﬁcantly reduced medication
errors with these drugs (31.6%, 18/57 vs 7.0%, 5/71,
p=0.002).7 Another CDS tool, GFR+, automatically calcu-
lates and updates doses of key drugs based on renal
function. When evaluated by Roberts et al,8 this tool
improved dosing conformity for both gentamicin (63%,
46/73 vs 87%, 33/38, p=0.01) and vancomycin (47%,
16/34 vs 77%, 13/17, p=0.07).
Other CDS tools were not effective in reducing genta-
micin/vancomycin dosing errors. Some were even
potentially harmful. One CDS tool was a computerised
prescriber order entry (CPOE) system that displayed an
initial default dose for gentamicin and tobramycin in
the dose box on the electronic prescription. In a large
proportion (58%, 227/392) of prescriptions, the sug-
gested default dose had not been amended. This dose
was used in 51.6% (132/256) of prescriptions for
renal-insufﬁciency patients and 85.6% (113/132) of
these resulted in potential ADEs compared with 53.2%
(66/124) for the remaining prescriptions (p<0.0001).
For patients without renal impairment, use of the CDS
tool to determine doses was not signiﬁcantly better than
regular dosing. The dose was incorrect in 72.7% (165/
227) of CDS prescriptions compared to 77% (127/165)
in non-CDS prescriptions (p=0.4). Therefore, this tool
was a source of potential ADEs especially in renal-
insufﬁciency patients.9
Risks with gentamicin and vancomycin were identiﬁed
locally in a number of ways. An analysis of antibiotic-
associated medication incidents reported to the
centralised incident reporting systems of two large UK
teaching hospitals, including the study site, over 2 years,
was undertaken.10 One-third of dose/frequency errors
reported (32/96) at the study site were related to genta-
micin (n=16) and vancomycin (n=16). A local Failure
Modes and Effects Analysis for gentamicin identiﬁed
that risks with dose calculation and prescribing, espe-
cially in patients with renal impairment or obesity, were
greater than risks with preparation of infusions. The
implementation of electronic prescribing across the
hospital facilitated the development of computerised
dose calculators for these drugs to improve prescribing,
championed by the Lead Antimicrobial Pharmacist with
the support of the Antibiotic Usage Steering Group.
The aim of this study was to evaluate the impact of
these calculators on the accuracy of prescribing of genta-
micin and vancomycin initial doses.
METHODS
Study design
The study used a pre–postintervention design and was
undertaken at a 950-bed acute National Health Service
(NHS) teaching hospital in London. Prescriptions for
gentamicin initial dose and vancomycin initiation
regimen (loading dose and ﬁrst maintenance dose)
written during the 8-month period (1 January 2011–31
August 2011) before implementation of the dose calcu-
lators were retrospectively assessed for appropriateness.
Following implementation of gentamicin and vanco-
mycin dose calculators, and promotion throughout the
hospital, data on the appropriateness of prescriptions
for their initial doses were collected prospectively for a
2-month period (1 June 2013–2 August 2013). In add-
ition to loading doses, ﬁrst maintenance doses were
assessed as part of vancomycin initiation regimens. This
was considered important, as the ﬁrst maintenance dose
is essential in ensuring appropriate serum levels, and
that is reﬂected in that the new calculator provides both
loading and ﬁrst maintenance doses.
The study was categorised by the hospital Research
and Development Department as a clinical audit/service
evaluation. Thus, ethical approval was not required.
However, the study was registered with the Clinical
Effectiveness and Audit Department.
Inclusion/exclusion criteria
All adults without severe renal impairment (creatinine
clearance (CrCl) ≥20 mL/min and not receiving
haemo/peritoneal dialysis) who received parenteral gen-
tamicin or vancomycin (loading and at least one main-
tenance dose) were included in this study. Patients who
received gentamicin as antibiotic prophylaxis prior to
urinary catheterisation, and patients receiving gentami-
cin as part of a two times or three times/day endocardi-
tis treatment regimen were excluded. Patients who
received vancomycin as an oral dose, once-only intraven-
ous dose, or continuous infusion were also excluded.
Patients without recorded height and weight were
excluded, as these criteria are essential for calculating
ideal body weight (BW) required for dose calculation;
also excluded were those with a height less than
152.4 cm (5 ft).
Definitions
Incorrect doses of gentamicin and vancomycin have
been described in the literature as doses outside the
ranges of 10%9 and 33.3%.8 For the purposes of this
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study, an incorrect dose of gentamicin was deﬁned as
‘any dose more than 10% higher or lower than the
recommended dose as speciﬁed in the hospital guide-
lines’. An incorrect dose of vancomycin was deﬁned as
‘any dose more than 20% higher or lower than the
recommended dose as speciﬁed in the hospital guide-
lines’. These margins were chosen taking into account
that gentamicin and vancomycin have a narrow thera-
peutic index and that many patients receiving these
drugs have some element of renal-insufﬁciency. They
also consider that doses are usually rounded based on
the available dosage forms and the practicalities of dose
administration.
Sample size calculation
In order to perform power and sample size calculations,
data were collected retrospectively for 49 patients who
received (both prescribed and administered) gentamicin
and for 36 patients who received vancomycin. A power
analysis conducted using assumptions of 95% power iden-
tiﬁed that at each stage preintervention and postinterven-
tion, a minimum sample of 192 patients who received
gentamicin and a minimum sample of 141 patients who
received vancomycin were required to detect a 30%
reduction in error incidence with each drug.
Study intervention
Calculators for gentamicin and vancomycin doses were
implemented in the hospital as an Excel application on
the hospital intranet. This is accessed by users from a
menu within the Electronic Prescribing and Medicines
Administration system (EPMA) of the Electronic Patient
Records (EPR) iSOFT Clinical Manager, which gives
access to patient demographics, hospital visit histories,
clinical notes, laboratory results and drug prescribing
and administration records. Prescribers are directed to
the calculators through a written note within the elec-
tronic prescription for each drug. The calculators are
not automatically populated from demographic or
laboratory data entered elsewhere within EPR. The cal-
culator uses patient information manually entered by
the prescriber, including age, actual BW, height and
serum creatinine (SrCr) to provide the appropriate dose
and frequency for each patient based on their weight
and CrCl. These calculators can be used with either
metric or imperial units, and are gender-speciﬁc. Once
required data are entered, the calculator will automatic-
ally determine the appropriate weight to be used
(actual, ideal or adjusted), CrCl, recommended dose
(loading and ﬁrst maintenance for vancomycin), recom-
mended dosing interval and duration of vancomycin
infusion (to avoid possible Red man syndrome). The
dose given by the calculator is the dose recommended
by the hospital antimicrobial guidelines.11
The hospital antimicrobial guidelines include instruc-
tions for dosing gentamicin and vancomycin. Ideal BW
should be used for dosing and CrCl calculation, unless
the patient is underweight (below ideal BW) when
actual BW is used or overweight (actual BW >20% over
ideal BW) when adjusted BW is used. Estimated BW can
only be used when other options are not available. The
initial gentamicin dose is calculated depending on
patient’s appropriate weight and CrCl, which is calcu-
lated using the Cockcroft-Gault equation.12 Although
there are more accurate methods (eg, insulin clear-
ance13), it is the method recommended by the hospital
guidelines for routine measurement of renal function.
The loading dose of vancomycin is calculated based on
actual BW. If the patient is ‘unﬁt’ to be weighed, ideal
BW is used, unless the patient looks underweight, in
which case estimated BW is used. Vancomycin ﬁrst main-
tenance dose is calculated based on the patient’s appro-
priate weight and CrCl. Details of equations and
calculations used in the calculators are in table 1.
Calculator implementation
On 1 September 2011, the calculators were ﬁrst available
on the hospital intranet. The calculators were promoted
locally by pharmacists in speciﬁc clinical areas, particu-
larly in haematology/oncology, where gentamicin is
widely prescribed for the treatment of neutropenic
sepsis. In February 2013, a link was created between
EPMA and the relevant page on the intranet, enabling
prescribers to access the required calculator on the same
screen as the EPR. Junior doctors joining the hospital in
February 2013 were informed about the calculators
during their induction programmes for safe prescribing.
In May 2013, a non-mandatory instruction to use the
calculator was added to gentamicin and vancomycin
orders on EPMA, and the availability of the calculators
was advertised on the intranet news page and via an
email to all doctors. Moreover, information about the
calculators and how to use them, as well as the precalcu-
lator results, were presented at one of the hospital
Grand Rounds to encourage their use.
Data collection and processing
Data were collected using EPR (iSOFT Clinical Manager
1.4). Paper notes were also reviewed, if necessary, to
collect data not available within EPR (eg, missing weight
or height). A data collection form was developed,
piloted and optimised before formal data collection
started. Demographic data collected for each patient
included age, gender, weight, height, SrCr, clinical spe-
cialty and ward. Patients’ body mass index (BMI) was
also calculated. Details collected about antibiotic
therapy included the ﬁrst dose for gentamicin, and the
loading and ﬁrst maintenance doses for vancomycin.
Dose frequency was also documented. Doses were com-
pared with the hospital antibiotic guidelines valid at the
time of prescribing. If patient height was not recorded
on electronic or paper notes, patients were asked about
their height. If patients were able to self-report their
height, this height was used in the study. Estimated
weights and heights were used if they were recorded in
patient notes (eg, for critical-care patients).
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In the precalculator phase of the study, patients who
received gentamicin or vancomycin were identiﬁed
retrospectively from the Microbiology database of
patients for whom a gentamicin or vancomycin serum
level had been requested. A random sample of gentami-
cin initial doses and a random sample of vancomycin
initiation regimens that were prescribed during the
8 months prior to implementing the calculators were
assessed against the guidelines for accuracy. In the post-
calculator phase, patients were identiﬁed prospectively
through an electronic ﬁlter of all active antimicrobial
prescriptions. This ﬁlter was checked daily, and any
patient who was prescribed gentamicin and/or vanco-
mycin was reviewed on EPMA (and paper notes if neces-
sary) for eligibility. During the 2 months following
promotion of the calculators, the accuracy of gentamicin
initial doses and vancomycin initiation regimens were
assessed for all eligible patients (ﬁgure 1).
Data were transferred into SPSS, which was used for
analysis. Quality-assurance procedures were undertaken
to assure the quality and accuracy of the data transferred.
The correct dose was calculated for each patient based
on hospital guidelines. Then, the difference between the
prescribed dose and the calculated dose was determined.
Based on its deviation from the guideline-recommended
dose, each dose was categorised as an underdose (>10%
under for gentamicin and >20% under for vancomycin),
overdose (>10% over for gentamicin and >20% over for
vancomycin), or correct dose (≤10%± for gentamicin
and ≤20%± for vancomycin). Data on number of times
the intranet calculator pages were visited were provided
by the hospital senior Web Developer.
Data analysis
Statistical data analysis was performed using SPSS V.21.
Binary logistic regression was used to assess the signiﬁ-
cance of the difference between the number of correct
doses, overdoses and underdoses, before and after
implementation of the calculators. It was also used to
produce ORs for these results. χ2 Analysis and Fisher’s
exact test were used to assess the signiﬁcance of the dif-
ference between the patients’ gender, ethnicity and
Table 1 Equations/calculations used in gentamicin and vancomycin dose calculators
Variable Underlying equation/calculation
Ideal body weight (kg)14 ▸ With height in feet/inches=[males 50 kg, females 45.5 kg]+2.3 kg for every inch in height
over 5 ft
▸ With height in centimetres=[male 50 kg, female 45.5 kg]+[(2.3×height in cm above 152.4)/
2.54]
Adjusted body weight
(kg)15*
= ideal body weight (kg)+0.4 [(actual body weight (kg)−ideal body weight (kg)]
Creatinine clearance
(mL/min)12
¼ 140 Age ðyearsÞ Weight ðkgÞ  F
Serumcreatinine ðmmol=LÞ F ¼ 1:04 for females and 1:23 formales
CrCl (mL/min) Dose and dosing interval
Gentamicin initial dose11 >80 5.0 mg/kg every 24 h
60–80 4.0 mg/kg every 24 h
40–60 3.5 mg/kg every 24 h
30–40 2.5 mg/kg every 24 h
20–30 4.0 mg/kg every 48 h
Actual body
weight (kg) <60 60–90 >90
Vancomycin loading
dose11 16
Loading dose 1000 mg 1500 mg 2000 mg
Fluid (NaCl or
glucose)
250 mL 500 mL 500 mL
Infusion period 120 min 180 min 240 min
Pump rate 125 mL/h 167 mL/h 125 mL/h
CrCl
(mL/min)
Dose
(mg)
Dosing
interval (h)
Fluid
(mL)
Infusion
period
(min)
Pump rate
(mL/h)
Vancomycin maintenance
dose11 16
>110 1500 12 500 180 167
90–110 1250 12 250 150 100
75–89 1000 12 250 120 125
55–74 750 12 250 90 167
40–54 500 12 250 60 250
30–39 750 24 250 90 167
20–29 500 24 250 60 250
*Also called dose-determining weight.
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prescriber specialty, before and after the calculators’
implementation. The same tests were also used to
measure the signiﬁcance of the difference between the
number of correct doses among different patient groups
before and after the calculators. Two-sample t test was
used to evaluate the difference in the age, BMI and
CrCl of patients, before and after the calculators. The
level of signiﬁcance was chosen as 5%.
Figure 1 Study participant flow chart.
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RESULTS
In total, 707 patients were included in the study; 410
received gentamicin (195 before and 215 after the calcu-
lator implementation) and 297 received vancomycin
(155 before and 142 after the calculator implementa-
tion). While Haematology/Oncology were overall the
most frequent prescribers of gentamicin (37.6%,
n=154), Medicine was the specialty in which vancomycin
was most frequently prescribed (30.3%, n=90). Further
details in table 2.
The gentamicin calculator page on the hospital intra-
net was visited 333 times during the 2-month period fol-
lowing implementation of the calculator. Correct
gentamicin doses increased from 38.5% (75/195)
before to 55.8% (120/215) after the calculator imple-
mentation, OR=2.02, p<0.001 (table 3).
The vancomycin calculator page on the hospital intra-
net was visited 388 times in the post calculator data col-
lection period. Correct vancomycin loading doses
increased from 41.9% (65/155) before to 67.6% (96/
142) after the calculator implementation, OR=2.89,
p<0.001. Correct vancomycin ﬁrst maintenance doses
increased from 44.5% (69/155) to 66.9% (95/142),
OR=2.52, p<0.001. The whole vancomycin initiation
regimen was correct (both loading and ﬁrst mainten-
ance doses were correct) in 23.9% (37/155) of patients
before and 47.9% (68/142) after the calculator imple-
mentation, OR=2.93, p<0.001 (table 4).
The vancomycin initiation regimen was considered
incorrect in three scenarios: loading dose is correct and
ﬁrst maintenance dose is incorrect: 18.1% before (28/
155) and 19.7% after (28/142) implementation of the
calculator; loading dose is incorrect and ﬁrst mainten-
ance dose is correct: 20.6% before (32/155) and 19%
after (27/142) calculator implementation; or loading
dose and ﬁrst maintenance dose are both incorrect:
37.4% before (58/155) and 13.4% after (19/142) calcu-
lator implementation (table 5).
Table 2 Demographic data for included patients
Category
Gentamicin
before (%)
n=195
Gentamicin
after (%)
n=215 p Value
Vancomycin
before (%)
n=155
Vancomycin
after (%)
n=142 p Value
Gender
Male 117 (60.0) 97 (45.1) 0.003 87 (56.1) 81 (57.0) 0.907
Female 78 (40.0) 118 (54.9) 68 (43.9) 61 (43.0)
Age±SD (years) 55.4±17.3 57.6±18.5 0.211 60.5±17.3 57.7±16.6 0.159
BMI±SD (kg/m2) 25.8±6.0 26.2±6.0 0.546 26.4±45.9 27.9±6.5 0.030
CrCl±SD (mL/min) 97.3±51.7 90.6±48.2 0.176 84.6±42.4 100.7±43.0 0.001
Ethnicity
White 133 (68.2) 144 (67.0) 0.833 100 (64.5) 106 (74.6) 0.060
Black 37 (19.0) 49 (22.8) 0.396 30 (19.4) 28 (19.7) 1.000
Asian 10 (5.1) 13 (6.0) 0.831 6 (3.9) 5 (3.5) 1.000
Other 7 (3.6) 4 (1.9) 0.364 8 (5.2) 2 (1.4) 0.107
Not specified 8 (4.1) 5 (2.3) 0.400 11 (7.1) 1 (0.7) 0.006
Specialty
Haematology/
oncology
99 (50.8) 55 (25.6) <0.001 39 (25.2) 16 (11.3) 0.003
Critical care 45 (23.1) 24 (11.2) 0.001 10 (6.5) 3 (2.1) 0.089
Medicine 16 (8.2) 65 (30.2) <0.001 44 (28.4) 46 (32.4) 0.528
Surgery 14 (7.2) 27 (12.6) 0.073 22 (14.2) 27 (19.0) 0.277
Liver 8 (4.1) 7 (3.3) 0.794 15 (9.7) 13 (9.2) 1.000
Women/child 6 (3.1) 18 (8.4) 0.033 1 (0.6) 2 (1.4) 0.608
Renal 3 (1.5) 1 (0.5) 0.350 0 (0) 0 (0) –
Neuroscience 3 (1.5) 13 (6) 0.021 14 (9.0) 25 (17.6) 0.038
Cardiology 1 (0.5) 5 (2.3) 0.219 10 (6.5) 10 (7.0) 1.000
BMI, body mass index; CrCl, creatinine clearance.
Table 3 Analysis of the accuracy of gentamicin initial doses
Category
Before (%)
n=195
After (%)
n=215 OR 95% CI p Value
Correct dose 75 (38.5) 120 (55.8) 2.02 1.36 to 3.00 <0.001
Overdose 83 (42.6) 62 (28.8) 0.55 0.36 to 0.82 0.004
Underdose 37 (19.0) 33 (15.3) 0.77 0.46 to 1.30 0.331
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A subanalysis was undertaken for patients at higher
risk including elderly (≥65 years), renally-impaired
(CrCl<60 mL/min) and obese (BMI≥30 kg/m2). No sig-
niﬁcant differences in the rate of gentamicin correct
doses before and after the calculator implementation
were found between elderly (14, 31.1% and 31, 68.9%)
and non-elderly (61, 40.7% and 89, 59.3%) patients
(p=0.248), patients with (13, 35.1% and 24, 64.9%) and
without (62, 39.2% and 96, 60.8%) renal impairment
(p=0.644), or obese (17, 43.6% and 22, 56.4%) and non-
obese (58, 37.2% and 98, 62.8%) patients (p=0.462).
There were also no signiﬁcant differences in the rate of
vancomycin correct regimens before and after the calcu-
lator between elderly (9, 38.9% and 24, 61.1%) and
non-elderly (28, 27.3% and 44, 72.7%) patients
(p=0.247), patients with (6, 46.2% and 7, 53.8%) and
without (31, 33.7% and 61, 66.3%) renal impairment
(p=0.379), or obese (5, 20% and 20, 80%) and non-obese
(32, 40% and 48, 60%) patients (p=0.068).
DISCUSSION
The initial dose accuracy for both gentamicin and
vancomycin signiﬁcantly improved after implementation
of new calculators providing CDS to prescribers at an
NHS teaching hospital. Incorrect initial doses of genta-
micin were reduced from 61.5% to 44.2% (p<0.001).
Incorrect loading doses of vancomycin were reduced
from 58.1% to 32.4% (p<0.001), while incorrect ﬁrst
maintenance doses were reduced from 55.5% to 33.1%
(p<0.001). Incorrect vancomycin initiation regimens
were reduced from 76.1% to 52.1% (p<0.001). The cal-
culator pages on the hospital intranet were frequently
accessed in the postcalculator phase. The activities
undertaken to promote the calculators and make them
compatible with the electronic prescribing system are
anticipated to have a role in such access.
Different CDS tools have shown improvements in genta-
micin and vancomycin dosing. A previous UK study found
that introducing an online gentamicin dose calculator led
to a 300% improvement in dosing accuracy (30%, 15/50
precalculator to 92%, 46/50 postcalculator) at an NHS
hospital. The calculator in this study required the same
data as the current study (ie, gender, age, weight, height,
SrCr) to provide the correct dose. Prophylactic doses were
also excluded from the study.17 However, it was conducted
only on surgical wards, had a relatively small sample size
(only 50 patients in each phase) and no statistical analysis
was conducted. Another study conducted in Taiwan inves-
tigated the impact of an online gentamicin dose calculator
incorporated into the hospital CPOE system, using a phar-
macokinetic formula to provide the correct dose. The
main outcome measure was the number of gentamicin
orders that resulted in undesirable serum levels. The cal-
culator reduced undesirable levels from 32.7% (152/465)
to 13.5% (40/297).18 Nevertheless, the study was con-
ducted only in intensive care units and used a compound
pharmacokinetic equation, which might be more suitable
only for speciﬁc patient groups. In addition, no statistical
analysis was performed.
A US study by Frankel et al19 showed an improvement
in initial vancomycin dosing at the ED after the
Table 4 Analysis of the accuracy of vancomycin initial doses
Category
Before (%)
n=155
After (%)
n=142 OR 95% CI p Value
Loading dose
Correct dose 65 (41.9) 96 (67.6) 2.89 1.80 to 4.65 <0.001
Overdose 5 (3.2) 5 (3.5) 1.10 0.31 to 3.86 0.888
Underdose 85 (54.8) 41 (28.9) 0.33 0.21 to 0.54 <0.001
First maintenance dose
Correct dose 69 (44.5) 95 (66.9) 2.52 1.57 to 4.04 <0.001
Overdose 56 (36.1) 32 (22.5) 0.51 0.31 to 0.86 0.010
Underdose 30 (19.4) 15 (10.6) 0.49 0.25 to 0.96 0.037
Initiation regimen (both loading and first maintenance doses)
Correct 37 (23.9) 68 (47.9) 2.93 1.79 to 4.81 <0.001
Incorrect 118 (76.1) 74 (52.1) 0.34 0.21 to 0.56 <0.001
Table 5 Subanalysis of the accuracy of vancomycin initiation regimens
Category
Before (%)
n=155
After (%)
n=142 OR 95% CI p Value
LD correct and MD correct 37 (23.9) 68 (47.9) 2.93 1.79 to 4.81 <0.001
LD correct and MD incorrect 28 (18.1) 28 (19.7) 1.11 0.62 to 1.99 0.716
LD incorrect and MD correct 32 (20.6) 27 (19.0) 0.90 0.51 to 1.60 0.725
LD incorrect and MD incorrect 58 (37.4) 19 (13.4) 0.26 0.14 to 0.46 <0.001
LD, loading dose; MD, first maintenance dose.
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introduction of CPOE with vancomycin weight-based
orders. The CPOE doses showed 51.1% (120/235) com-
pliance to the recommended initial dosing guideline
compared with 34.9% in the pre-CPOE doses (82/235,
p<0.001). Compared to the vancomycin calculator in the
current study, this CPOE was only valid for loading doses
since it did not adjust doses for height or CrCl, and it
was examined only in the ED. The ‘Pharmacist-to-Dose’
intervention in the Vincent et al7 study showed a signiﬁ-
cant reduction in aminoglycoside and vancomycin
dosing errors. However, the study had a relatively small
sample size (49 patients preintervention and 48 postin-
tervention) and lacked details on how many correct and
incorrect doses were associated with each drug (only
combined data were provided). The intervention by
Roberts et al8 (GFR+) also reduced dosing errors with
gentamicin and vancomycin. However, the reduction in
vancomycin errors was not statistically signiﬁcant
(p=0.07). The number of patients in each group was
relatively small (73 pre-GFR+ and 38 post-GFR+ for gen-
tamicin and 34 pre-GFR+ and 17 post-GFR+ for vanco-
mycin). Moreover, the study used a modiﬁed version of
Cockcroft-Gault equation that caps SrCr to a minimum
of 60 μmol/L and also a complex gentamicin dosing
model that was derived from local population kinetics,
which limits the generalisability of its ﬁndings.
The vast majority of incorrect vancomycin loading
doses in the current study were underdoses (94.4%,
85/90). Similarly, 90.8% (3143/3461) of incorrect
vancomycin doses in the Fuller et al6 study were under-
doses. Although actual BW is the ideal method for calcu-
lating initial vancomycin doses, a ﬁxed dose of 1000 mg
is commonly used in the ED.20 Most patients in a US
study conducted in the ED (87.5%, 210/240) were admi-
nistered an initial vancomycin dose of 1000 mg.20 In the
current study, 1000 mg dose was used in 40.4% of all
loading doses (120/297), 75.8% (91/120) of them were
underdoses, which shows that this practice is not
common only at the ED. The use of 1000 mg loading
doses was signiﬁcantly reduced from 52.3% (81/155)
before to 27.5% (39/142) after implementation of the
calculator (p<0.001). However, the extent of underdos-
ing here was relatively unchanged from 79% before to
69.2% after the intervention. Likewise, the study by
Frankel et al19 identiﬁed that initial doses of 1000 mg
vancomycin were prescribed in 206/235 (87.7%) of
cases and 72.3% of these were underdoses. Following
implementation of CPOE, that rate of prescribing of
1000 mg doses fell to 128/235 (54.5%), of which 59.4%
were underdoses. The current study was the ﬁrst to
assess ﬁrst maintenance dose as part of the initial dose
of vancomycin in addition to loading dose, so no com-
parison with past studies is possible.
The introduction of CDS tools into healthcare is a
complex interaction between people, technology and
organisational workﬂow. The automatic provision of CDS
tools as part of the clinician workﬂow is seen as the most
important element for successful CDS implementation.8
In this study, efforts were made to incorporate the use of
calculators into the prescriber workﬂow by adding a
direct link to them from EPMA and setting an instruction
to use them on the electronic prescription forms.
However, further work is required to fully integrate these
calculators into the electronic prescribing system (eg,
automatic population of appropriate patient demo-
graphic data and laboratory results). The reported advan-
tages of CDS tools in optimising drug dosing may cause
physicians to over-rely on their suggestions. However, pre-
scribers should always be careful when using CDS tools,
particularly for prescribing high-risk and narrow-
therapeutic-index medications, as studies have high-
lighted that these tools may lead to unintended negative
results.9 21 22
One limitation of this study is that it was not possible,
due to technical barriers, to identify whether visitors to
the calculator pages actually used the tools to aid pre-
scribing. Therefore, the improvements in gentamicin
and vancomycin initial-dose accuracy cannot be deﬁni-
tively linked to the use of the calculators, and so further
work should be undertaken to link visits to these calcula-
tors to actual patient dosing. However, the signiﬁcant
improvements in dose accuracy after implementation of
the calculators provide an indication that they contribu-
ted to this improvement, especially as no other proactive
initiatives to improve gentamicin and vancomycin dosing
took place during the same period. In addition, genta-
micin and vancomycin dosing guidance was the same
preintervention and postintervention. Prospective data
collection would have been the ideal method to collect
data in the precalculator and postcalculator phases. As
this was not feasible, the use of a retrospective method
to collect data and a different source to identify patients
(ie, Microbiology database) in the precalculator phase
was considered a limitation of this study. Selection of the
precalculator study population differed from that asso-
ciated with the postcalculator intervention group. The
population in the precalculator phase was retrospectively
identiﬁed from records of patients who had been pre-
scribed gentamicin or vancomycin during an 8-month
period and for whom a serum level had been requested.
However, the postcalculator group was identiﬁed pro-
spectively over a 2-month period using an antimicrobial
ﬁlter within EPR to identify all active prescriptions for
gentamicin and vancomycin, regardless of whether a
serum level had been requested. The differences in these
methodologies may have resulted in different patient and
prescriber groups, which may have had an impact on the
ﬁndings of this study. However, this impact is likely
minimal. The guidelines for gentamicin and vancomycin
prescribing applied across all patient groups included in
the study. Where local specialty-speciﬁc guidelines for
gentamicin and vancomycin were in place (eg, continu-
ous vancomycin infusions in critical care), these prescrip-
tions and patients were excluded from the study. The
precalculator data had to be collected retrospectively due
to the unavailability of EPMA on all hospital wards at that
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time. Moreover, the calculators were already available
online, although not promoted or linked with EPMA,
when the decision to conduct the study was taken. Thus,
the retrospective-review dates (1 January 2011–31 August
2011) were chosen before the date calculators were ﬁrst
available online. The Microbiology database was the only
source available to retrospectively identify patients pre-
scribed gentamicin and vancomycin.
There were some differences in demographics pre-
calculators and postcalculators, including patient gender
in the gentamicin group, BMI and CrCl in the vanco-
mycin group, and prescriber specialty in both groups.
These differences are probably due to the different data
collection methods used, but it is not anticipated that
they affected the overall results. The comparison
between high-risk and non-high-risk patients showed
that age, weight and renal function did not affect the
dosing accuracy. In addition, the differences in specialty
rates are unlikely to have affected the overall outcomes
because the number of correct doses in the specialty
with the highest number of patients (Haematology/
Oncology in the gentamicin group and Medicine in the
Vancomycin group) was higher postcalculator, although
the overall proportion of doses was higher or similar
precalculator.
Data from the literature show that giving the correct
dose of gentamicin or vancomycin improves clinical out-
comes. A Scottish study showed that cure rate was higher
in patients for whom the gentamicin dose was given
according to protocol (95.7%, 22/23) compared to
those for whom it was not (75%, 24/32), p=0.06. Less
toxicity was observed in patients for whom the doses
were adjusted according to protocol (4.3%, 1/23 vs
28.1%, 9/32, p<0.05).23 Fuller et al6 demonstrated
that patients who received a vancomycin overdose
(>20 mg/kg) stayed in hospital longer (p=0.005), were
more likely to spend ≥3 days in hospital (OR=1.49,
p=0.006) and more likely to die (OR=1.88, p=0.004).
They also showed that correct doses were associated with
signiﬁcantly higher numbers of therapeutic serum levels
(21.6% vs 14.3%, p=0.004). However, this study did not
assess the independency of the association between
these outcomes and vancomycin overdoses. With the
exception of one study, which showed a reduction in
undesirable serum levels with the intervention,18 none
of the intervention studies discussed above have assessed
patient clinical outcomes. Since this study focused on
identifying the accuracy of prescribing gentamicin and
vancomycin initial doses according to an evidence-based
guideline, it did not assess the difference in patient clin-
ical outcomes between precalculator and postcalculator
doses (eg, correct serum level, treatment-success rate).
The aim of treatment with these drugs is to administer
safe initial doses to ensure prompt, effective treatment
of potentially life-threatening infections while minimis-
ing the risk of toxicity. Ensuring ﬁrst doses are accurately
calculated is the ﬁrst stage of safe, effective treatment.
The assessment of serum levels after subsequent doses
to exclude toxicity, and resolution of infection, are
subject to many patient and process variables and were
beyond the scope of this study. However, further work
would be needed to assess the direct impact of this inter-
vention on patient clinical outcomes. As the postcalcula-
tor phase was conducted directly after completing the
calculators’ implementation, the dosing accuracy and
calculators’ usage should be reassessed after 12–24
months to evaluate the long-term impact of the
calculators.
CONCLUSION
This study suggests that gentamicin and vancomycin
dose calculators signiﬁcantly improved the prescribing
of initial doses of these agents. Healthcare organisations
implementing electronic prescribing systems should con-
sider including such CDS tools in their programmes to
support the prescribing of these high-risk drugs.
However, this study did not assess the long-term impact
of the calculators and their clinical outcomes.
Therefore, further work is needed to evaluate the pro-
longed effect of these calculators, and to determine the
association between their use and improvement of clin-
ical outcomes.
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